Sulodexide fails to demonstrate renoprotection in overt type 2 diabetic nephropathy (Q35720773)

9 August 2017

Sulodexide fails to demonstrate renoprotection in overt type 2 diabetic nephropathy (English)

1 reference

Collaborative Study Group

9 August 2017

Rory Wolfe

2

0 references

15

object named as

Collaborative Study Group

1 reference

9 August 2017

10

Thomas B Wiegmann

1 reference

9 August 2017

David K Packham

1

1 reference

9 August 2017

Anne T Reutens

3

1 reference

9 August 2017

Tomas Berl

4

1 reference

9 August 2017

Hiddo Lambers Heerspink

5

1 reference

9 August 2017

Richard Rohde

6

1 reference

9 August 2017

Sara Ivory

7

1 reference

9 August 2017

Julia Lewis

8

1 reference

9 August 2017

Itamar Raz

9

1 reference

9 August 2017

Juliana C N Chan

11

1 reference

9 August 2017

Dick de Zeeuw

12

1 reference

9 August 2017

Edmund J Lewis

13

1 reference

9 August 2017

Robert C Atkins

14

1 reference

9 August 2017

27 October 2011

1 reference

Journal of the American Society of Nephrology

9 August 2017

1 reference

9 August 2017

23

1 reference

9 August 2017

123-130

1 reference

9 August 2017

1

1 reference

Sulodexide ameliorates early but not late kidney disease in models of radiation nephropathy and diabetic nephropathy

9 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269919

Telmisartan, ramipril, or both in patients at high risk for vascular events

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269919

Sulodexide: a renewed interest in this glycosaminoglycan

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269919

One year course of oral sulodexide in the management of diabetic nephropathy.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269919

Excerpts from the United States Renal Data System 2004 annual data report: atlas of end-stage renal disease in the United States

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269919

Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269919

Global prevalence of diabetes: estimates for the year 2000 and projections for 2030

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269919

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269919

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269919

Nephropathy in patients with type 2 diabetes mellitus

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269919

A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269919

Glycosaminoglycan sulodexide decreases albuminuria in diabetic patients

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269919

Effects of high glucose on the production of heparan sulfate proteoglycan by mesangial and epithelial cells

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269919

Heparin modulates proliferation and proteoglycan biosynthesis in murine mesangial cells: molecular clues for its activity in nephropathy.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269919

Treatment with a glycosaminoglycan formulation ameliorates experimental diabetic nephropathy

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269919

Random-effects models for longitudinal data

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269919

Sulodexide oral administration influences blood viscosity and fibrinolysis

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269919

Aliskiren combined with losartan in type 2 diabetes and nephropathy

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269919

Effects of sulodexide in patients with type 2 diabetes and persistent albuminuria

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269919

Rationale for and study design of the sulodexide trials in Type 2 diabetic, hypertensive patients with microalbuminuria or overt nephropathy

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269919

Antiproteinuric effect of oral paricalcitol in chronic kidney disease

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269919

The effect of ruboxistaurin on nephropathy in type 2 diabetes

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269919

The effect of rosiglitazone on urine albumin excretion in patients with type 2 diabetes mellitus and hypertension

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269919

Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269919

Standards of medical care for patients with diabetes mellitus

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269919

Sulodexide in the treatment of intermittent claudication. Results of a randomized, double-blind, multicentre, placebo-controlled study

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269919

Oral sulodexide reduces albuminuria in microalbuminuric and macroalbuminuric type 1 and type 2 diabetic patients: the Di.N.A.S. randomized trial

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269919

A pilot study of the effect of the glycosaminoglycan sulodexide on microalbuminuria in type I diabetic patients.

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269919

Sulodexide for Kidney Protection in Type 2 Diabetes Patients With Microalbuminuria: A Randomized Controlled Trial

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269919

Human pharmacokinetics of glycosaminoglycans using deuterium-labeled and unlabeled substances: evidence for oral absorption

15 November 2018

1 reference

12 December 2020

Glycosaminoglycans Delay the Progression of Nephropathy in NIDDM

1 reference

12 December 2020

A randomized, controlled study of sulodexide therapy for the treatment of diabetic nephropathy

1 reference

12 December 2020

Effect of glycosaminoglycans on urinary albumin excretion in insulin-dependent diabetic patients with micro- or macroalbuminuria

1 reference

12 December 2020

Heparin reduces glomerular infiltration and TGF-beta protein expression by macrophages in puromycin glomerulosclerosis

1 reference

12 December 2020

Heparin stimulates the synthesis and modifies the sulfation pattern of heparan sulfate proteoglycan from endothelial cells

1 reference

12 December 2020

Glycosaminoglycans prevent morphological renal alterations and albuminuria in diabetic rats

1 reference

12 December 2020

IPO-V2: a prospective, multicenter, randomized, comparative clinical investigation of the effects of sulodexide in preventing cardiovascular accidents in the first year after acute myocardial infarction

1 reference

12 December 2020

Identifiers

DOI

10.1681/ASN.2011040378

1 reference

9 August 2017

1 reference

9 August 2017

1 reference